Innoviva (NASDAQ:INVA – Get Rating) and Cogent Biosciences (NASDAQ:COGT – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk. Analyst Ratings This is a summary of current recommendations for […]
Innoviva, Inc. (NASDAQ:INVA – Get Rating) major shareholder Alexander J. Denner acquired 7,000 shares of the business’s stock in a transaction dated Monday, June 5th. The shares were bought at an average price of $13.04 per share, for a total transaction of $91,280.00. Following the acquisition, the insider now owns 7,207,000 shares of the company’s […]
Innoviva, Inc. (NASDAQ:INVA – Get Rating) major shareholder Alexander J. Denner bought 50,000 shares of the company’s stock in a transaction dated Thursday, May 25th. The stock was bought at an average cost of $13.09 per share, with a total value of $654,500.00. Following the acquisition, the insider now directly owns 7,050,000 shares of the […]
Innoviva, Inc. (NASDAQ:INVA – Get Rating) major shareholder Alexander J. Denner bought 50,000 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The stock was purchased at an average price of $13.09 per share, with a total value of $654,500.00. Following the transaction, the insider now directly owns 7,050,000 shares […]
Principal Financial Group Inc. lowered its position in Innoviva, Inc. (NASDAQ:INVA – Get Rating) by 3.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 402,826 shares of the biotechnology company’s stock after selling 14,984 shares during the period. […]